Institute of Physiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany (K.B.F.); and Department of Anesthesiology, Intensive Care and Pain Medicine, Westphalian Wilhelminian University Muenster, University Hospital Muenster, Muenster, Germany (A.U.S.)
Institute of Physiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany (K.B.F.); and Department of Anesthesiology, Intensive Care and Pain Medicine, Westphalian Wilhelminian University Muenster, University Hospital Muenster, Muenster, Germany (A.U.S.).
J Pharmacol Exp Ther. 2019 May;369(2):300-310. doi: 10.1124/jpet.118.254664. Epub 2019 Mar 5.
Blood transfusions are a daily practice in hospitals. Since these products are limited in availability and have various, harmful side effects, researchers have pursued the goal to develop artificial blood components for about 40 years. Development of oxygen therapeutics and stem cells are more recent goals. Medline (https://www.ncbi.nlm.nih.gov/pubmed/?holding=ideudelib), ClinicalTrials.gov (https://clinicaltrials.gov), EU Clinical Trials Register (https://www.clinicaltrialsregister.eu), and Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au) were searched up to July 2018 using search terms related to artificial blood products in order to identify new and ongoing research over the last 5 years. However, for products that are already well known and important to or relevant in gaining a better understanding of this field of research, the reader is punctually referred to some important articles published over 5 years ago. This review includes not only clinically relevant substances such as heme-oxygenating carriers, perfluorocarbon-based oxygen carriers, stem cells, and organ conservation, but also includes interesting preclinically advanced compounds depicting the pipeline of potential new products. In- depth insights into specific benefits and limitations of each substance, including the biochemical and physiologic background are included. "Fancy" ideas such as iron-based substances, O microbubbles, cyclodextranes, or lugworms are also elucidated. To conclude, this systematic up-to-date review includes all actual achievements and ongoing clinical trials in the field of artificial blood products to pursue the dream of artificial oxygen carrier supply. Research is on the right track, but the task is demanding and challenging.
输血是医院的日常实践。由于这些产品供应有限，且具有各种有害的副作用，因此研究人员大约 40 年来一直致力于开发人造血液成分。氧气治疗和干细胞的开发是更近的目标。Medline（https://www.ncbi.nlm.nih.gov/pubmed/?holding=ideudelib）、ClinicalTrials.gov（https://clinicaltrials.gov）、欧盟临床试验注册处（https://www.clinicaltrialsregister.eu）和澳大利亚新西兰临床试验注册处（http://www.anzctr.org.au）使用与人工血液制品相关的搜索词进行了搜索，截至 2018 年 7 月，以确定过去 5 年中最新的和正在进行的研究。然而，对于那些已经广为人知且对该研究领域的理解具有重要意义或相关性的产品，读者将及时参考一些发表于 5 年前的重要文章。本综述不仅包括临床相关物质，如血红素氧化载体、全氟化碳类氧载体、干细胞和器官保存，还包括一些有趣的、具有临床前进展的化合物，描绘了潜在新产品的发展前景。深入了解每种物质的具体益处和局限性，包括生化和生理背景。还阐明了“花哨”的想法，如铁基物质、O 微泡、环糊精或沙蚕。总之，这篇系统的最新综述包括人造血液制品领域的所有实际成果和正在进行的临床试验，以追求人造氧载体供应的梦想。研究正在正确的轨道上，但任务艰巨且具有挑战性。
